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Abstract (100-200 words) 16 
Characterization of controlled release formulations used for intra-articular (IA) drug administration 17 
is challenging. Bio-relevant synovial fluids (BSF), containing physiologically relevant amounts of 18 
hyaluronic acid, phospholipids and proteins, were recently proposed to simulate healthy and 19 
osteoarthritic conditions. This work aims to evaluate the performance of different controlled release 20 
formulations of methylprednisolone (MP) for IA administration, under healthy and disease states 21 
simulated conditions. Microspheres differed in grade of poly(lactide-co-glycolide) and in the 22 
theoretical drug content (i.e. 23 or 30% w/w). Their performance was compared with the 23 
commercially available suspension of MP acetate (MPA). Under osteoarthritic state simulated 24 
condition, proteins increased the MPA release and reduced the MPA hydrolysis rate, over 48h. 25 
Regarding microspheres, the release patterns over 40 days were significantly influenced by the 26 
composition of BSF. The pattern of the release mechanism and the amount released was affected by 27 
the presence of proteins. Protein concentration affected the release and the concentration used is 28 
critical, particularly given the relevance of the concentrations to target patient populations, i.e. 29 
patients with osteoarthritis. 30 
 31 
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1. Introduction 36 
Corticosteroids locally administered by intra-articular injections represent one of the major treatment 37 
for arthritis, osteoarthritis or musculoskeletal disorders to reduce pain and inflammation, facilitate 38 
motion and function [1]. Due to lymph drainage of synovial fluids, the drug residence into the joint 39 
is very short even when prodrugs are used [2,3] and, thus, systemic side effects have been frequently 40 
reported [2]. To overcome this limitation, the controlled release of drugs loaded in microspheres made 41 
of poly(lactide-co-glycolide) [PLGA] have been proposed [4,5] and the efficacy and bioavailability 42 
of methylprednisolone loaded in PLGA matrix has been demonstrated in an animal model [6]. The 43 
optimization of these drug delivery systems is challenging, as compendial in vitro drug release tests 44 
are not described in the main Pharmacopoeias. The sample-and-separate or modified USP 4 apparatus 45 
methods using a buffer as release medium and sink conditions have been proposed in the literature 46 
for the screening of different PLGA-based microspheres formulations and the evaluation of batch-to-47 
batch variability [7]. An in vitro release experimental set-up reflecting the in vivo conditions, which 48 
would assist in formulation development and prediction of the in vivo performance, is missing. For 49 
example, sink conditions which are generally applied in quality control testing are not bio-relevant in 50 
some anatomic sites, such as in the sub-cutaneous or the intra-muscular environment [8,9]. Moreover, 51 
simple buffers do not reflect the composition of physiological fluids in healthy or disease states. In 52 
the case of joints synovial fluids of healthy subjects and osteoarthritic patients, it has been 53 
demonstrated that these fluids significantly differ qualitatively and quantitatively in their composition 54 
[10], and they present different physicochemical properties, such as viscosity, osmolarity, surface 55 
tension and pH [11]. The simulation of the synovial fluid in both healthy and disease states can play 56 
a crucial role in the development of in vitro release/dissolution testing for intra-articular formulations. 57 
Up to date, there are no synovial fluid-simulating media approved by Regulatory Agencies, and 58 
limited information on the impact of their composition on the drug release and dissolution are 59 
reported. For instance, the addition of hyaluronic acid in a buffer system is the main focus of the 60 
published simulated synovial fluids used as release media [12–15]. Recently, bio-relevant synovial 61 
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fluids containing physiologically relevant amounts of hyaluronic acid, phospholipids and proteins 62 
were proposed to evaluate the release profile of an approved triamcinolone suspension and predict 63 
performance of intra-articular formulations [16].  64 
The main goal of the present study was to evaluate the in vitro release behaviour of PLGA 65 
microspheres loaded by methylprednisolone, in media simulating synovial fluids under healthy and 66 
disease state conditions. Microspheres were prepared by using two grades of PLGA, differing in the 67 
lactide/glycolide ratio, and encapsulating different amounts of drug. Preliminarily, the proposed bio-68 
relevant synovial fluids were used to test the release of methylprednisolone acetate from the aqueous 69 
suspension of the drug available on market (Depo-Medrone), approved for the treatment of joint 70 
disease such as osteoarthritis. For both the types of formulations (i.e. drug loaded PLGA microspheres 71 
and drug aqueous suspension) the influence of the main components of bio-relevant synovial fluids 72 
was evaluated.  73 
2. Materials and Methods 74 
1.1. Materials 75 
Two different grades of poly(D,L-lactide-co-glycolide) (PLGA) were kindly donated by Corbion 76 
Purac Biomaterials (Netherlands): Purasorb PDLG 5002 (PLGA 5050) and Purasorb PDLG 7502 77 
(PLGA 7525; their characteristics are presented in Table S1). A grade of hydroxypropyl 78 
methylcellulose at low viscosity (Methocel K100 LV, HPMC) was kindly provided by Colorcon 79 
(Italy). Methylprednisolone (MP) was obtained by Farmalabor (Italy), and Depo-Medrone 80 
(methylprednisolone acetate [MPA] aqueous suspension, 40 mg/ml) was purchased from Pfizer Ltd 81 
(UK). Hyaluronidase from bovine testes type VIII (lyophilized powder, range of activity between 300 82 
and 1000 Units/mg) and -globulin from bovine blood were purchased by Sigma-Aldrich (UK). 83 
Sodium hyaluronate 95% (HA) and bovine serum albumin (BSA) were obtained from Fischer 84 
Scientific (UK). Egg phosphatidylcholine (PC) was purchased from Lipoid (Germany) and 85 
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polysorbate 80 (Tween® 80) from Croda (Italy). Glass microfiber membrane and syringe filter (GF/D, 86 
pore size 2.7 m) and regenerated cellulose syringe filter (RC, pore size 0.45 m) were obtained from 87 
Whatman GE Healthcare Life Sciences (UK). Nitrocellulose membrane filters (NC, pore size 1.2 m) 88 
were purchased by Millipore (Italy). Syringe filters of 0.2 and 0.45 m pore size were purchased by 89 
VWR International (USA). All the other chemicals were bought by Fischer Scientific (UK) and all 90 
the solvents used were of analytical grade. 91 
1.2. Methods 92 
1.2.1. Bio-relevant synovial fluids preparation 93 
Bio-relevant synovial fluids (BSF) were prepared according to the compositions and the protocols 94 
reported by Nikolettos I. [16]. BSF reflecting healthy (H-BSF) and osteoarthritic (OA-BSF) 95 
conditions contained physiologically relevant amounts of HA and PC with their ratio being 1:1.7 and 96 
1:0.6 for OA and H conditions, respectively, -globulin and BSA. The pH of H-BSF was 7.4 and the 97 
pH of OA-BSF was 8. The OA-BSF was also prepared without BSA and -globulin [OAwp-BSF] in 98 
order to investigate the influence of the presence of proteins on the drug solubility and its release 99 
from the formulations under test. 100 
1.2.2. Bio-relevant synovial fluid-sample treatment 101 
The hyaluronidase type VIII solution was freshly prepared by dissolving the enzyme at the 102 
concentration of 1 mg/mL in sodium phosphate buffer at pH 7.0 with 77 mM NaCl and 0.01% w/v 103 
BSA. Biorelevant synovial fluid samples were treated with hyaluronidase solution, in order to 104 
facilitate sample filtration and HPLC analysis [17]. Hyaluronidase solution prepared according to 105 
manufacturer (initial concentration of 300-1000 U/mg) was added to the samples being treated, to 106 
obtain a final concentration of 150 units/mL of the enzyme. 107 
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1.2.3. Solubility study 108 
The MP solubility was studied by the shaking-flask method in healthy and disease states BSF and in 109 
PBS (pH 7.4) containing 0.02% w/v of SDS (PBS/SDS). Briefly, after the addition of an excess 110 
amount of the drug to each medium studied, the suspension was vortexed and incubated in a 111 
horizontal shaking water bath (Fisher Scientific, UK) at 37.00.5°C for 48h. Samples were withdrawn 112 
at 24 and 48h, filtered through a 0.45 m RC (samples from PBS/SDS) or 2.7 m GF (samples from 113 
BSF) filters to remove the undissolved particles and the amount of dissolved drug was quantified by 114 
HPLC. Before injection, samples from BSF were treated with a hyaluronidase solution (section 1.2.2), 115 
filtered through 0.45 m RC filter and diluted accordingly. Solubility studies were performed in 116 
triplicate. 117 
1.2.4. Preparation of drug loaded microspheres 118 
MP loaded microspheres were produced by the solid-in-oil-in-water (S/O/W) method, as described 119 
by Cilurzo et al., with minor modifications [5]. Briefly, MP was dispersed in 1 mL of 20 wt. % PLGA 120 
solution in dichloromethane by sonication with an ultrasound probe (UP200St, 7 mm diameter, 121 
Hielscher, G) at an amplitude of 20% for 5 s, and cooling the sample in an ice-bath. The amount of 122 
MP was fixed to obtain a theoretical drug loading of 23 or 30% (Table 1). The S/O suspension was 123 
added dropwise into 25 mL of 2.5 % w/v solution of HPMC at 4.00.5 °C, under mechanical stirring 124 
with a propeller (600 rpm, 5min). The S/O/W system was poured into 250 mL of ultrapure water 125 
cooled at 4.00.5 °C and the temperature was gradually increased till 301 °C. Hardened particles 126 
were recovered by filtration under vacuum using a 1.2 m NC membrane filter, washed with ultrapure 127 
water, suspended in water and freeze-dried (Martin Christ Alpha 1-4 LSC Plus, G). Dried samples 128 
were stored under vacuum at 53 °C until use. All formulations were prepared in duplicate. 129 
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1.2.5. Determination of polymer molecular weight 130 
Molecular weight distribution of raw polymers and loaded microspheres before and after the 40-day 131 
release studies were measured by gel permeation chromatography (GPC). Samples of about 5-6 mg 132 
were dissolved in dichloromethane and filtered through a 0.45 m PTFE syringe filter prior the 133 
injection, to remove the undissolved particles. The instrument was equipped with a G1379A degasser, 134 
a G1310A isocratic pump, a G1313A auto-sampler, a G1316A thermostated column compartment 135 
and double detector: refractive index detector G1362A and UV/visible detector (G1314A) set at 136 
λ=230 nm. Three columns (Phenogel 300x4.6 mm, Phenomenex, I) with gel pore size of 104 Å, 103 137 
Å and 500 Å were connected in series. The mobile phase was dichloromethane at a flow rate of 0.35 138 
mL/min at a temperature of 25.00.1 °C. An injection volume of 70 L was used. The weight-average 139 
molecular weight (Mw) and the number-weight molecular weight (Mn) of each sample were calculated 140 
using monodisperse polystyrene standards with Mw ranging from 486 to 188,000 Da and a GPC-141 
Addon HP ChemStation software (Hewlett-Packard Co., USA) to compute molecular weight 142 
distribution. Dispersity index (DI) was calculated by the ratio between Mw and Mn. 143 
1.2.6. Microspheres size distribution and morphology 144 
The mean particle size and the size distribution of microspheres suspended in 0.05% polysorbate 80 145 
solution were evaluated by the single particle optical sensing (SPOS) technique, using an Accusizer 146 
770 (PSS Inc. USA). The results were expressed as undersize cumulative percentages and the 147 
dispersion of the size distribution as Span [Eq. (1)]. 148 
𝑆𝑝𝑎𝑛 =  
𝑑90−𝑑10
𝑑50
         Eq. (1) 149 
where d10, d50 and d90 represent the diameters at 10, 50 and 90% of the size volume distribution, 150 
respectively.  151 
All the samples were analysed in triplicate and the results reported as mean ± SD. 152 
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Microspheres morphology before and after the 40-day release was investigated by scanning electron 153 
microscopy (SEM, JEOL 6480 LV, JEOL, USA), at an electron beam voltage of 10 kV. Dried 154 
samples were rigidly mounted on an aluminium stub using a carbon adhesive and placed under 155 
vacuum overnight in order to remove residual moisture. Before images collection and to improve 156 
their resolution, samples were coated with a thin layer of gold, using a sputter coater S150B (Edwards, 157 
UK) for 5 min. 158 
1.2.7. MP content in the microsphere formulations 159 
The amount of MP encapsulated in the microspheres was quantified by the HPLC method described 160 
in section 1.2.10. MP was extracted from 10 mg of dried microspheres placed in 50 mL of a 161 
water/acetonitrile mixture (1:1) for 24h at room temperature. Each sample was filtered through a 0.2 162 
m nylon syringe filter before the HPLC analysis. All the measurements were performed in triplicate. 163 
The experimental MP loading % and the encapsulation efficiency (EE) % were calculated based on 164 
Eq. (2) and Eq. (3), respectively.  165 
 166 
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙 𝑀𝑃 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 % =  
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑀𝑃 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑥 100  Eq. (2) 167 
 168 
𝐸𝐸 % =  
𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑀𝑃 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 𝑖𝑛 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑀𝑃 
𝑥 100     Eq. (3) 169 
1.2.8. ATR-FTIR spectroscopy 170 
IR spectra were recorded using a SpectrumTM One spectrophotometer (PerkinElmer, USA) equipped 171 
with a diamond crystal mounted in a ATR cell (PerkinElmer, USA). Samples of MP and drug loaded 172 
microspheres were scanned with a resolution of 4 cm-1 over a wavenumber region between 4000 and 173 
650 cm-1. 64 scans for each sample were collected. Baseline and ATR correction were performed on 174 
each spectrum.  175 
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1.2.9. In vitro release studies 176 
All the release studies were carried out by the sample-and-separate method in a 50 mL-glass bottle 177 
closed by screwed cap at 37.00.5 °C, in a horizontal shaking water bath set at the mild agitation of 178 
250 strokes/min. An exact volume of MPA aqueous suspension from the marketed formulation 179 
(Depo-Medrone), corresponding to 2 mg of MP, was placed in 20 mL of PBS/SDS or BSF (H-BSF, 180 
OA-BSF and OAwp-BSF). After 0.5, 1, 2, 3, 7, 24 and 48h a 4 mL-sample was withdrawn through a 181 
2.7 m GF filter and the sampled volume was replaced with fresh medium. The quantification of 182 
MPA and its hydrolysis product (MP) was performed by HPLC (section 1.2.10). The formation rate 183 
constant of MP (kMP) was calculated from the first order fitting of MP amount over time [Eq. (4)] 184 
using OriginPro® 2015 software (OriginLab Corporation, USA).  185 
 186 
𝑌 =  𝑌max(1 − 𝑒
𝑘𝑀𝑃𝑡)         Eq. (4) 187 
 188 
where Y is the % amount of MP formed at time t and Ymax is the maximum % of MP formed over 189 
time. The goodness of the fit was evaluated by the adjusted R2 and by the residual sum of squares. 190 
The release profiles of MPA were also corrected for hydrolysis by transformation of the MP 191 
quantified amount to MPA amount. 192 
Similarly, drug loaded microspheres were exactly weighed to obtain 2 mg of MP, properly dispersed 193 
in 1 mL of the buffer used for the preparation of each BSF and then transferred in the release medium, 194 
reaching a final volume of 20 mL. After 1, 3, 7, 24h, 3, 7 days and then once a week until 40 days, a 195 
4 mL-sample was withdrawn as described above. Each sample from the studies in BSF was treated 196 
with a hyaluronidase solution prior to HPLC analysis (section 1.2.2). A release study of formulation 197 
MS 50-23 in PBS with 0.02% w/v SDS was also performed. Sink conditions were achieved for all 198 
the release studies. All release studies were performed in triplicate.  199 
The release rate constant was calculated according to Higuchi’s model (Eq. 5). 200 
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 201 
𝑀𝑡
𝑀∞
= 𝑘𝑡0.5           Eq. (5) 202 
where Mt represents the amount of MP released at time t, M∞ is the amount of MP loaded in the 203 
matrix and k is the constant rate of drug diffusion. 204 
 205 
After 40 days and prior to the recovery of the microspheres, the pH of each medium was measured 206 
and reported as mean ± SD. Microspheres were then recovered by centrifugation (Hettich 1605-13 207 
Universal 32 Centrifuge, G) at 8,000 rpm for 10 min at room temperature, washed three times with 208 
ultra-pure water, filtered (1.2 m RA membrane) and dried under vacuum before GPC and SEM 209 
analyses.  210 
1.2.10. HPLC analysis 211 
MP and MPA were quantified by HPLC, using an Agilent HP1200 series (Agilent, UK) equipped 212 
with a G1312A binary pump, a G1329A auto-sampler, a G1316A thermostated column compartment 213 
and a G1315D UV detector. A Phenomenex Inertsil ODS-2 (C18, 250 x 4.60 mm, 5 m) column 214 
was used for the reversed phase chromatography [18]. The mobile phase was a mixture of water and 215 
methanol in the volume ratio of 70:30, at the flow rate of 1 mL/min. The injection volume was 50 L 216 
and the temperature 35 °C. The detection of MP and MPA was performed at 247 nm. For the BSF 217 
samples, a gradient method was applied after the isocratic elution of MP and MPA, increasing the 218 
water content up to 90% over 12 min. MP and MPA calibration curves in the range of 1-10 g/mL 219 
were freshly prepared in each medium prior each experiment (R2 > 0.99). Standard solutions of MP 220 
and MPA in BSF were prepared by adding the relative amount of MP or MPA working solution at 221 
20 g/mL (in PBS) to the BSF and treating them as reported previously (section 1.2.2). 222 
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1.2.11. Statistical analysis 223 
Release data from marketed formulation were analysed by one-way ANOVA followed by Tukey test 224 
for pair-wise means comparison (𝛼=0.05), using OriginPro® 2015 software (OriginLab Corporation, 225 
USA).  226 
Comparison of two experimental means from solubility data and release data from microsphere 227 
formulations were performed using unpaired student t-test to determine two-tailed p values at 95% 228 
confidence level. 229 
3. Results and discussion 230 
3.1. Solubility study 231 
The equilibrium solubility of MP in healthy and disease states BSF (with and without proteins) was 232 
reached after 24h and the results are summarized in Table 2. Among the different BSF studied, the 233 
highest value of MP solubility was found in the osteoarthritic medium with proteins (p<0.05 in all 234 
the cases); while the lowest in the same medium without proteins (OAwp-BSF vs H-BSF p=0.035 235 
and OAwp-BSF vs OA-BSF p<0.01). The MP solubility in OAwp-BSF was similar to the one in 236 
PBS/SDS (p=0.190), in accordance also with the value reported in literature [19]. The lower solubility 237 
values in the media without proteins compared to the ones where they were present can be attributed 238 
to the fact that particularly BSA can bind molecules through hydrophobic and electrostatic 239 
interactions [20] and act like a solubilizing agent, as in the case of ketoconazole, danazole, felodipine 240 
[21], itraconazole [22] and cholesterol [23]. Considering that MP has an albumin binding of 241 
approximately 78% [24], BSA can act similarly in the tested BSF influencing its solubility, as also 242 
revealed by the higher value resulted in H-BSF compared to PBS/SDS (H-BSF vs PBS/SDS p=0.011, 243 
Table 2). Being a surfactant [25], PC impacts MP solubility, even though in a lower extent, as 244 
demonstrated by the comparison of the values in OA-BSF and H-BSF (Table 2). 245 
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3.2. Microsphere formulations: preparation and characterization 246 
The S/O/W method allowed to prepare particles suitable for the intra-articular administration [4], 247 
with a size ranging between 10 and 43 µm, a narrow size distribution and satisfactory drug 248 
encapsulation (Table 1).  249 
SE micrographs of MP loaded microspheres (Fig. 1) showed that all the particles were spherical in 250 
shape. When the lowest amount of MP was loaded (formulation MS 50-23 and MS 75-23), small 251 
pores were evident on the surface of the particles, while when the highest amount of drug was 252 
encapsulated (formulation MS 50-30), particles had many holes since that the polymeric matrix 253 
seemed to be not completely formed.  254 
Experimental MP loading and encapsulation efficiency were slightly higher when PLGA 5050 was 255 
used (formulation MS 50-23) instead of PLGA 7525 (formulation MS 75-23, Table 1), probably due 256 
to the lower rigidity of PLGA with a similar content between lactic and glycolic acids (Table S1). 257 
The increase of MP amount led to a higher loading of the drug in the microspheres with PLGA 5050 258 
(MS 50-30 vs MS 50-23), with an encapsulation efficiency comparable to the one obtained for 259 
formulation MS 75-23. The GPC data confirmed that the use of an ultrasound probe to prepare 260 
microspheres did not have a detrimental effect on polymers, since the Mw calculated for all the 261 
microsphere formulations were superimposable at time 0 (Table 4). Additionally, the ultrasounds or 262 
the evaporation of the solvent during microspheres’ formation did not change the solid state of MP 263 
that was encapsulated as Form I. This is evidenced by the three strong absorption bands between 1800 264 
and 1580 cm-1 of the ATR-FITR spectrum that were attributed to the stretching of carboxylic acid 265 
and ketone groups (1650 and 1720 cm-1, respectively) and to the aromatic bending (1592 cm-1) [Fig. 266 
2] [26]. 267 
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3.3. In vitro release studies 268 
3.3.1. Marketed formulation of methylprednisolone acetate 269 
The release profiles of MPA aqueous suspension in all BSF and PBS/SDS showed that both the 270 
release and the hydrolysis of MPA were depended on the medium composition (Fig. 3a). After 24h 271 
the highest MPA release from the suspension was observed in the OA-BSF (29.2±2.2%, p<0.05 272 
compared to the other media tested), whereas a lower and similar release was seen in the H-BSF and 273 
in PBS/SDS (22.6±1.6% and 21.6±1.9% respectively, p=0.557). This trend confirms the influence of 274 
proteins on drug release and this was even more evident from the significantly lower amount of MPA 275 
released in OAwp-BSF (8.2±1.2 %) compared to OA-BSF. In all media tested, MPA underwent 276 
hydrolysis according to first order kinetics (Fig. 3b). The rate of MP formation was medium-277 
depended (Table 3), with the MPA hydrolysis rate constant in H-BSF being significantly different 278 
than the hydrolysis rate constants in all the other media (p<0.05). These differences reveal the 279 
importance of the simulation of healthy and pathological status during the in vitro studies. After the 280 
correction of the release profiles of MPA to account for the hydrolysed drug (Table 3), at 48h the 281 
highest MPA release was observed in OA-BSF (p<0.05). MPA release from the suspension in the 282 
other media was lower, following the rank order: H-BSF, OAwp-BSF and PBS/SDS. The biorelevant 283 
simulation of the synovial fluid under healthy and osteoarthritic conditions is critical and the release 284 
in these conditions was significantly different than in a simple buffer with a surfactant (% corrected 285 
MPA release at 48h: PBS/SDS vs OA-BSF p=0.008 and PBS/SDS vs H-BSF p=0.023). The presence 286 
of proteins in the release medium led to an increased % amount of MPA released, suggesting that 287 
their presence should be carefully considered (OA-BSF vs OAwp-BSF p=0.038, Table 3). 288 
3.3.2. Methylprednisolone loaded PLGA microspheres 289 
In all tested media, a high burst release of MP from the formulation with the highest drug loading 290 
(MS 50-30) was observed in the first hour (Fig. 4a). This effect can be explained based on the IR 291 
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spectrum of this formulation in which the high intensities of MP bands at 1592 and 1650 cm-1 was 292 
attributed to the high amount of surface-associated drug particles (Fig. 2). Moreover, the high 293 
discontinuity of PLGA matrix at microspheres’ surface (Fig. 1) allowed the medium to enter quickly, 294 
fill the empty channels and dissolve the drug that then diffused out [27]. The burst effect of MS 50-295 
30 was less pronounced in OAwp-BSF (MP released in 1h in OA-BSF=47.5±0.7% and in OAwp-296 
BSF=29.4±1.1%, p<0.05), suggesting that the presence of proteins in the release medium influenced 297 
not only the drug solubility, but also the wettability of the matrix, as revealed by the SEM (Fig. 5a-298 
d). After the burst effect, MP release reached a plateau after 3 days only in H-BSF and OA-BSF 299 
(49.6±4.3% and 46.3±2.5% in H-BSF and OA-BSF, respectively). On the contrary, a constant release 300 
occurred in OAwp-BSF (k50-30_OAwp: 0.032±0.002 days
-0.5; R2=0.96±0.03). In this medium, a 301 
59.4±2.6% MP was released after 40 days, that is significantly higher than the % MP released in the 302 
other media (OAwp-BSF vs H-BSF p=0.004, OAwp-BSF vs OA-BSF p=0.048), revealing the effect 303 
of proteins on the amount of drug released from MS 50-30. 304 
Concerning the formulation MS 75-23, only the burst MP release of around 20% after the first hour 305 
was seen in the H-BSF (Fig. 4b). The SE micrograph of the microspheres recovered after 40 days in 306 
this medium showed that the particles had a completely smooth surface, called the “skin” type 307 
structure (Fig. 5e), probably due to a remodelling/healing process occurred in the plasticized particles 308 
over time [28]. This phenomenon determined the occlusion of the pores and the inability of the drug 309 
to be continuously released out of the particles. MS 75-23 behaved differently in OA-BSF as a typical 310 
tri-phasic release was noticed, with a burst effect similar to the other two media (22.4±0.2 % at t=1h, 311 
p>0.05), a lag-phase of about 7 days and a second release phase which fitted the Higuchi model (k75-312 
23_OA=0.051±0.024 days
-0.5; R2=0.90±0.04) [Fig 4b]. After day 21, a plateau on MP release was 313 
reached (37.5±2.3 %). In absence of proteins (OAwp-BSF), a completely different shape of the MP 314 
release profile was obtained: after the burst effect, a continuous release of MP without lag phase was 315 
obtained and the release data was well characterized by the Higuchi model (k75-23_OAwp=0.025±0.002 316 
days-0.5; R2=0.84±0.11, p>0.05 compared to k75-23_OA), indicating that the MP release was mostly 317 
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governed by the diffusion, as also reported for the MS 50-30. However, at day 40, the % MP released 318 
was similar to the one in OA-BSF (about 37%). This can be explained by both morphological analysis 319 
(Fig. 5f and h) and GPC data of the recovered microspheres (Table 4) which demonstrated that the 320 
degradation of PLGA 7525 occurred similarly in OA-BSF and OAwp-BSF, with a reduction of the 321 
molecular weight of about 7 KDa. 322 
Also in the case of MS 50-23, the MP release was dependent on the composition of the release 323 
medium (Fig. 4c), and a prolonged and controlled MP release was reached. The burst effect of about 324 
6% at 1h was similar in H-BSF, OA-BSF and PBS/SDS (p>0.05). The % MP released from these 325 
microspheres in the first hour and after day 1 were lower than the corresponding ones from the MS 326 
50-30 and MS 75-23. This difference can be attributed to the different distribution of the drug within 327 
the polymer matrix during the microsphere preparation when PLGA 5050 and the lowest theoretical 328 
drug loading was used (MS 50-23) [29]. In H-BSF and PBS/SDS, MP release started after a lag phase 329 
of about 28 days, revealing that for releasing the drug it was necessary that polymer chains 330 
degradation reached a certain critical PLGA Mw. According to the SEM of the recovered 331 
microspheres after 40 days (Fig. 5i and l), a bulk-erosion controlled release was observed, that is 332 
typical of microspheres made of PLGA with relatively low molecular weight (as PLGA 5050 used in 333 
this study) and encapsulating poorly soluble small molecules [30]. Despite the similarity in the release 334 
profiles, the microspheres did not behave in the same way in PBS/SDS and H-BSF, with microspheres 335 
recovered from H-BSF having a wrinkled surface compared to the ones from PBS/SDS (Fig. 5i and 336 
l). GPC data confirmed that MS 50-23 underwent a greater degradation in H-BSF than in the 337 
PBS/SDS, with a molecular weight loss of about 74% and 37%, respectively (Table 4). In the case 338 
of the MP release in BSF mimicking the disease state (OA-BSF), even though the burst effect was 339 
similar to the one observed in the simulated healthy conditions (H-BSF), MP release started after day 340 
7, reaching a 27.8±1.6 % MP released at day 40, indicating that the simulation of disease state had an 341 
impact on the release. The absence of proteins resulted in a decrease of the burst effect, as a burst of 342 
4.4% was measured in OAwp-BSF (p=0.004). Furthermore, in the same BSF medium, there was no 343 
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lag phase and the MP release was characterised by the Higuchi model (k50-23_OAwp=0.050±0.004 days
-344 
0.5; R2=0.95±0.05, Fig. 4c), with about 37% of MP released after 40 days. Conversely, the MP 345 
released from MS 50-23 in OA-BSF seemed to follow the tri-phasic release: burst effect, lag phase 346 
of about 1 week and second pulse zero-order release from day 7 to day 21, fitting the Higuchi model 347 
with k50-23_OA=0.119±0.014 days
-0.5 (R2=0.84±0.11). Afterwards, a plateau was reached (27.8±1.6 % 348 
after 40 days) probably due to the occurrence of healing processes, as evident in the SE micrograph 349 
(Fig. 5j). No significant differences in terms of Mw were detected in the microspheres recovered from 350 
OA-BSF and OAwp-BSF after 40 days (Table 4).  351 
The overall release data from the performed studies clearly indicated that the presence of proteins 352 
influenced significantly the drug release, both in terms of the amount released and the release 353 
mechanism of MP from all types of microspheres. The presence of proteins in the bio-relevant 354 
synovial fluid has to be carefully considered. Their interactions with other components of the synovial 355 
fluid are not completely understood, but they affect properties of the synovial fluid, such as the 356 
surface tension, and consequently the performance of a drug delivery system inside the joint [31,32]. 357 
For these reasons, the disease state BSF was prepared with and without the proteins. Proteins interact 358 
with hydrophobic polymers, such as PLGA, and they can be adsorbed in a selective and a competitive 359 
manner onto the surface of nanoparticulate PLGA systems, forming the so called “protein corona” 360 
[33]. Among them, BSA, which has a good sequence identity with human serum albumin, is adsorbed 361 
onto PLGA nanoparticles better than other proteins, such as -globulin [34,35]. Based on these 362 
considerations, it can be assumed that similar interactions could also occur in the release studies 363 
carried out in BSF, determining the different mechanisms in MP release from the different 364 
microsphere formulations. A tri-phasic MP release in OA-BSF was observed from formulations MS 365 
75-23 and MS 50-23, reaching a plateau at day 21 probably due to a polymer remodelling that closed 366 
the surface pores of microspheres, as previously discussed (Fig. 5f and j). These formulations after 367 
40 days of incubation in OAwp-BSF presented a sponge-like structure (Fig. 5g, h and k) which 368 
favours the release of MP according to a drug diffusion mechanism. For all the formulations, the 369 
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protein content of the tested media also influenced the Higuchi constants, with the highest values 370 
obtained when proteins were added to the medium. 371 
Both types of PLGA used in the microspheres (MS 50-23 and MS 50-23 prepared with PLGA 5050 372 
and MS 75-23 prepared with PLGA 7525) underwent a more pronounced degradation after incubation 373 
in H-BSF compared to the other media. The hydrolysis of PLGA ester bonds starts immediately upon 374 
contact with the release medium and the acidic degradation by-products accumulate within 375 
microsphere until a critical Mw is reached. As a result, the drop of micro-environmental pH catalyses 376 
the hydrolysis reaction, causing in some cases a heterogeneous degradation inside PLGA matrices 377 
[36,37]. The high viscosity of H-BSF could slow down the diffusion of PLGA oligomers allowing 378 
the establishment of the auto-catalysis phenomenon which accelerated PLGA degradation. 379 
Afterwards, the diffusion of PLGA degradation by-products outside microspheres determined the 380 
acidification of the H-BSF medium, which presents a low buffering capacity. On the other hand, in 381 
both the osteoarthritic media (OA-BSF and OAwp-BSF) the lower viscosity and the basic pH allowed 382 
a better oligomers’ diffusion out of microspheres and their further neutralization. This hypothesis is 383 
supported by the pH of the BSF measured after the 40-day release (Table 4). The massive degradation 384 
occurred in H-BSF determined the greater drop in the pH value compared to the osteoarthritic media.  385 
3. Conclusions 386 
In the design and quality control of long-term release drug delivery systems, the availability of in 387 
vitro testing to characterize their biopharmaceutical performance is fundamental. This aspect is of 388 
great importance in the case of PLGA microspheres intended to locally administer a drug in a specific 389 
anatomic site. In the case of joints, the composition of the synovial fluid depends on the state of the 390 
subject (healthy vs pathological state) and such differences can impact the efficacy of an intra-391 
articular medicinal product. In the present work, we proposed an advanced way to characterize MP 392 
loaded PLGA microspheres, simulating healthy and osteoarthritic status of the synovial fluid, that set 393 
the stage for the bio-relevant approach in an in vitro set up. The experimental results suggested that 394 
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the release from both the marketed and microsphere formulations was affected by the medium 395 
composition, with a significant impact by the presence of proteins on the release mechanism and the 396 
hydrolysis rate. Furthermore, the proposed bio-relevant conditions permitted to discriminate among 397 
all formulations and individuate a possible candidate able to control MP prolonged release over a 30 398 
day-period. 399 
  400 
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Figure captions 401 
 402 
Fig. 1 – SE micrographs of MP loaded microsphere formulations. (a: formulation MS 50-23; b: 403 
formulation MS 75-23; c: formulation MS 50-30). 404 
 405 
Fig. 2 – ATR-FTIR spectra of MP (black line), formulation MS 50-23 (blue line), formulation MS 406 
50-30 (red line) and formulation MS 75-23 (green line). 407 
 408 
Fig. 3 – Cumulative percentage of MPA released (a) and MP formed (b) in the tested media from 409 
Depo-Medrone® formulation (osteoarthritic BSF [OA-BSF]; osteoarthritic BSF without proteins 410 
[OAwp-BSF]; healthy state BSF [H-BSF]; PBS with 0.02% w/v SDS [PBS/SDS]). 411 
 412 
Fig. 4 – Cumulative percentage of MP released from formulation (a) MS 50-30, (b) MS 75-23 and 413 
(c) MS 50-23 in the tested media with the sample-and-separate method (osteoarthritic BSF [OA-414 
BSF]; osteoarthritic BSF without proteins [OAwp-BSF]; healthy state BSF [H-BSF]; PBS with 415 
0.02% w/v SDS [PBS/SDS]); insert graphs: close up of first 7h. 416 
 417 
Fig. 5 – SE micrographs of MP loaded microsphere formulation recovered after day 40 of release; 418 
formulation MS 50-30 in (a) H-BSF, (b) OA-BSF, (c) and (d) OAwp-BSF ad different magnitudes; 419 
formulation MS 75-23 in (e) H-BSF, (f) OA-BSF, (g) and (h) OAwp-BSF at different magnitudes; 420 
formulation MS 50-23 in (i) H-BSF, (j) OA-BSF, (k) OAwp-BSF and (l) PBS/SDS. 421 
  422 
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Table 1 – Characterization of microspheres in terms of particle size distribution (undersize 538 
cumulative percentage of the volume distribution), and polydispersity of the size distribution (Span). 539 
All the results are expressed as mean ± SD (n=3). 540 
 541 
Form. ID 
L/G 
ratio 
Drug loading Size distribution 
Theoretical 
(%, w/w) 
Actual 
(% w/w) 
EE% 
d10a 
(µm) 
d50b 
(µm) 
d90c 
(µm) 
Span 
MS 50-23 50:50 23 18.8±0.3 81.7±1.2 11.1±1.2 14.4±1.7 31.6±3.7 1.2±0.1 
MS 75-23 75:25 23 17.0±0.4 73.5±1.9 10.7±1.0 23.1±2.8 42.5±3.7 1.4±0.1 
MS 50-30 50:50 30 22.1±0.5 73.8±1.8 9.6±0.2 18.6±0.5 36.4±2.4 1.4±0.1 
a 10% of microparticle population were smaller than the number reported; 542 
b 50% of microparticle population were smaller than the number reported; 543 
c 90% of microparticle population were smaller than the number reported. 544 
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Table 2 –MP solubility in different media after 24h, expressed as mean ± SD (n=3). 546 
 547 
Medium 
Ratio % 
HA:PC 
Ratio % 
BSA:-globulin 
MP solubility  
(g/mL) 
PBS/SDS - - 118.7  5.3* 
OAwp- BSF 95:5 - 112.8  0.9* 
OA-BSF 95:5 87:13 161.3  0.2 
H-BSF 98:2 87:13 136.9  3.2 
*MP solubility in PBS/SDS and OAwp-SDS were not statistically different (p>0.05) 548 
Osteoarthritic BSF [OA-BSF]; osteoarthritic BSF without proteins [OAwp-BSF]; healthy state BSF [H-BSF]; PBS with 549 
0.02% w/v SDS [PBS/SDS]. 550 
 551 
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Table 3 – Maximum % MPA released from Depo-Medrone® corrected for hydrolysis and goodness 553 
(adjusted R2 (Adj R2) and residual sum of square (RSQ)) of the first order fitting of the MP formation 554 
(kMP). Results are reported as mean ± SD (n=3).  555 
 556 
Release 
medium 
MPA (%) kMP (h-1) Adj R2 RSQ 
PBS/SDS 29.4±2.7 0.053±0.003 0.99±0.00 0.001±0.000 
OAwp-BSF 34.7±2.2 0.166±0.015 0.87±0.04 0.163±0.060 
OA-BSF 43.1±3.7 0.084±0.051 0.93±0.02 0.051±0.019 
H-BSF 36.6±2.0 0.293±0.080 0.93±0.01 0.018±0.006 
Osteoarthritic BSF [OA-BSF]; osteoarthritic BSF without proteins [OAwp-BSF]; healthy state BSF [H-BSF]; PBS with 557 
0.02% w/v SDS [PBS/SDS]. 558 
 559 
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Table 4 – GPC data of PLGA microspheres after preparation (t=0 day) and after the 40-day release 561 
in different media. Molecular weight distribution is reported as weight average molecular weight 562 
(Mw) and polydispersity index (DI). The pH value of the release medium was measured after the 40 563 
day-release and reported as mean ± SD (n=3).  564 
 565 
Release  
medium 
Time 
(days) 
MS 50-23 MS 75-23 MS 50-30 
Mw 
(KDa) 
DI pH 
Mw 
(KDa) 
DI pH 
Mw 
(KDa) 
DI pH 
-- 0 20.1 1.6 -- 22.2 1.6 -- 20.2 1.5 -- 
PBS/SDS 40 12.6 1.4 7.23±0.03 n.d. -- n.d n.d -- n.d  
OAwp-BSF 40 11.8 1.7 7.93±0.04 15.1 1.7 7.98±0.04 14.1 1.7 7.98±0.02 
OA-BSF 40 10.5 1.5 7.39±0.05 13.7 1.7 7.38±0.02 12.6 1.6 7.43±0.12 
H-BSF 40 5.2 1.3 5.85±0.09 9.7 1.6 5.76±0.24 4.7 1.3 6.03±0.03 
Osteoarthritic BSF [OA-BSF]; osteoarthritic BSF without proteins [OAwp-BSF]; healthy state BSF [H-BSF]; PBS with 566 
0.02% w/v SDS [PBS/SDS]. 567 
 568 
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Supplementary material 594 
 595 
Thermal analysis 596 
Thermal analyses of raw polymers were performed using DSC 1 Stare System (METTLER 597 
TOLEDO, CH). The instrument was calibrated with indium for melting point and heat of fusion. 598 
Samples of about 10 mg exactly weighted were crimped in 40 L aluminium pan and scanned from 599 
room temperature to 90 °C at 20 K/min to erase polymers’ thermal history. After a cooling step, 600 
samples were re-heated up to 60 °C at 10 K/min. Glass transition temperature were calculated on 601 
the second heat scan and reported as inflection point value. All the analyses were performed under 602 
inert atmospheres of nitrogen (80 mL/min) and using an empty aluminium pan as reference 603 
material.  604 
 605 
Gel permeation chromatography 606 
Molecular weight distribution of raw polymers were measured by gel permeation chromatography. 607 
Samples of about 5-6 mg were dissolved in dichloromethane and filtered through a 0.45 m PTFE 608 
syringe filter prior the injection, to remove undissolved particles. Three columns (Phenogel 609 
300x4.6 mm, Phenomenex, I) with gel pore size of 104 Å, 103 Å and 500 Å were connected in 610 
series. The mobile phase was dichloromethane at a flow rate of 0.35 mL/min at a temperature of 611 
25.00.1 °C. An injection volume of 50 L was used. The instrument was equipped with a double 612 
detector: refractive index detector and UV/visible detector set at λ=230 nm. The weight-average 613 
molecular weight (Mw) and the number-weight molecular weight (Mn) of each sample were 614 
calculated using monodisperse polystyrene standards with Mw ranging from 486 to 188,000 Da and 615 
a software to compute molecular weight distribution (Agilent, USA). Dispersity index (DI) resulted 616 
from the ratio between Mw and Mn. 617 
  618 
 35 
Results 619 
 620 
Table S1 enlists the main properties of the selected PLGAs. As expected, PLGA 75:25 had a higher 621 
glass transition temperature with a lower heat capacity associated with the glass-rubber transition, 622 
indicating a higher rigidity of the polymer chains compared to PLGA 50:50 [1]. Both polymers 623 
were quite homogenous in terms of molecular weight distribution, with a Mw of about 20 KDa. 624 
 625 
Table S1- Main properties of the two types of PLGA selected to prepare the microspheres for this 626 
study. 627 
PLGA 
DL-lactide 
content* 
Tg (°C) ∆Cp (J/g·K) 
Mw 
(KDa) 
DI 
50:50 47-53 %mol 36.5±0.1 0.602±0.027 20.4±0.4 1.5±0.0 
75:25 72-78 %mol 37.7±0.1 0.458±0.021 23.6±0.3 1.7±0.2 
*as reported by the supplier. 628 
 629 
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